Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Latest Press Releases

Newron to initiate Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain (NLBP)

22/12/2008
English ENG German GER

Newron Consortium Grant

22/12/2008
English ENG German GER

Investor News

Please click here to view Newron share price information on SIX.